Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.61 |
| ▸ | CA12 | O43570 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.49 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.49 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.49 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8418962 | 0.91 | CA12 (0.67) | HTR6CA12CA2CA1TSHR | |
| (Phenylsulfonyl)Benzene SCHEMBL11592754 | 0.84 | HTR6 (0.78) | HTR6CA12CA2CA1TSHR | |
| SCHEMBL19681874 | 0.83 | GAA (0.70) | CA12CA2CA1KMT2AMEN1 | |
| SCHEMBL13169865 | 0.82 | HTR6 (0.54) | HTR6CA12CA2CA1TSHR | |
| SCHEMBL18270518 | 0.81 | ALDH1A1 (0.55) | CA12CA2CA1TSHRKMT2A | |
| SCHEMBL9806707 | 0.81 | HTR6 (0.67) | HTR6CA12CA2CA1TSHR | |
| SCHEMBL5051390 | 0.81 | HTR6 (0.93) | HTR6CA12CA2CA1TSHR | |
| Hydrochloric Acid SCHEMBL28149921 | 0.79 | CA2 (0.53) | CA12CA2CA1KMT2AMEN1 | |
| SCHEMBL8026965 | 0.79 | KEAP1 (0.69) | HTR6CA12CA2CA1KMT2A | |
| SCHEMBL4164729 | 0.78 | ALDH1A1 (0.68) | HTR6CA12CA2CA1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103384668-B | compounds and compositions for inhibition of NAMPT | 福马TM有限责任公司 | 2017-05-31 | — | — | CN | disclosed |
| CN-106243023-A | For suppressing guanidine compound and the compositions of NAMPT | 福马TM有限责任公司 | 2016-12-21 | — | — | CN | disclosed |
| CN-103717574-A | Novel compounds and compositions for the inhibition of nampt | FORMA TM LLC | 2014-04-09 | — | — | CN | disclosed |
| CN-103384668-A | Novel compounds and compositions for inhibiting NAMPT | FORMA THERAPEUTICS INC | 2013-11-06 | — | — | CN | disclosed |
| CN-103261160-A | guanidine compounds and compositions for inhibition of NAMPT | FORMA THERAPEUTICS INC | 2013-08-21 | — | — | CN | disclosed |
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| CN-100536839-C | Urea derivatives as integrin alpha 4 antagonists | ALMIRALL PRODESFARMA SA (ES) | 2009-09-09 | — | — | CN | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-7223759-B2 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| CN-1531425-A | Urea derivatives as integrin alpha 4 antagonists | ������ҩ������˾ | 2004-09-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | HTR6 755/4885CA12 3409/4885CA2 1359/4885 |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | HTR6 755/4885CA12 3409/4885CA2 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.